Last reviewed · How we verify
ABA, open-label (OL)
Nivolumab is an immune checkpoint inhibitor that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.
Nivolumab is an immune checkpoint inhibitor that blocks the PD-1 receptor, allowing the immune system to attack cancer cells. Used for Metastatic melanoma, Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | ABA, open-label (OL) |
|---|---|
| Also known as | Orencia |
| Sponsor | Bristol-Myers Squibb |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking the PD-1 receptor, nivolumab prevents cancer cells from evading immune surveillance, leading to an enhanced anti-tumor response. This mechanism is thought to be particularly effective in treating various types of cancer, including melanoma and non-small cell lung cancer. The exact molecular mechanisms underlying nivolumab's efficacy are still being studied.
Approved indications
- Metastatic melanoma
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
- Hypothyroidism
- Increased lipase
- Increased amylase
- Hypophosphatemia
- Hypokalemia
Key clinical trials
- Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABA, open-label (OL) CI brief — competitive landscape report
- ABA, open-label (OL) updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI